Biotech RadarJobs updated

COMPANY

MBX Biosciences

HQ: Carmel, IN source · mbxbio.com ↗ · Midwest

Clinical Phase 3

12 open jobs · last seen Oct 23, 2026 · 10 sources

Keywords: metabolic obesity Hypoparathyroidism Postbariatric Hypoglycemia Renal Impairment MBX 2109 Canvuparatide MBX 1416 (INN imapextide) MBX 4291

Profile checked Oct 10, 2026

Since the raise (Sep 25, 2025): 12 of 12 open jobs were first seen after it.

12Open jobs$199.9MRaised (2 yrs)8Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Payroll SpecialistCarmel, Indiana Oct 22, 2026Oct 23, 2026
Director, Clinical Operations (Obesity)Burlington, MAOct 21, 2026Oct 22, 2026
Associate Director, QA Oversight for QCBurlington, MAOct 16, 2026Oct 17, 2026
Scientist, Peptide ChemistryGreater Boston Area Oct 13, 2026Oct 14, 2026
Senior Scientist, Drug SubstanceBurlington, MAOct 2, 2026Oct 9, 2026

See all 12 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Board tracked Radar started tracking this company’s job board (12 open jobs at last check). source ↗
  2. Trial start Phase 3: A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism source ↗
  3. Raise Follow-on offering: $199.9M (total, as published), announced Sep 25, 2025. Source: company release on GlobeNewswire. source ↗
  4. Trial start Phase 1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity source ↗
  5. Trial start Phase 2: Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) source ↗
  6. Trial start Phase 2: Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism source ↗
  7. Trial start Phase 2: Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism source ↗
  8. Trial start Phase 1: Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function source ↗
  9. Trial start Phase 1: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects source ↗
  10. Trial start Phase 1: Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 12

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Payroll SpecialistCarmel, Indiana Oct 22, 2026Oct 23, 2026Not stated
Director, Clinical Operations (Obesity)Burlington, MAOct 21, 2026Oct 22, 2026Not stated
Associate Director, QA Oversight for QCBurlington, MAOct 16, 2026Oct 17, 2026Not stated
Scientist, Peptide ChemistryGreater Boston Area Oct 13, 2026Oct 14, 2026Entry
Senior Scientist, Drug SubstanceBurlington, MAOct 2, 2026Oct 9, 2026Senior
Quality Systems & Compliance SpecialistBurlington, MAOct 1, 2026Oct 9, 2026Mid
Senior Clinical Trial ManagerBurlington, MAOct 1, 2026Oct 9, 2026Senior
Regulatory Affairs FellowBurlington, MA Sep 29, 2026Oct 9, 2026Senior
Clinical ScientistBurlington, MAAug 28, 2026Oct 9, 2026Mid
Senior Manager, Clinical Data ManagementBurlington, MAAug 17, 2026Oct 9, 2026Senior
Director, BioanalyticalBurlington, MAAug 17, 2026Oct 9, 2026Senior
Associate Director, Statistical ProgrammingBurlington, MAAug 17, 2026Oct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $199.9M. Last 2 years.

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT06531941Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With HypoparathyroidismPhase 2Active, not recruitingOct 31, 20242028-05 (estimated)
NCT07699471A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With HypoparathyroidismPhase 3RecruitingAug 26, 20262028-01 (estimated)
NCT07029412Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)Phase 2CompletedAug 26, 2025Apr 18, 2026 (actual)
NCT07142707A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With ObesityPhase 1RecruitingSep 3, 2025Oct 30, 2026 (estimated)
NCT06465108Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With HypoparathyroidismPhase 2CompletedAug 8, 2024May 23, 2025 (actual)
NCT06496217Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal FunctionPhase 1CompletedJun 13, 2024Sep 4, 2025 (actual)
NCT06036784Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy SubjectsPhase 1CompletedSep 18, 2023Nov 14, 2024 (actual)
NCT05158335Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult SubjectsPhase 1CompletedNov 10, 2021Jun 20, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at MBX Biosciences on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback